Equities

Gilead Sciences Inc

0QYQ:LSE

Gilead Sciences Inc

  • Price (USD)150.70
  • Today's Change2.70 / 1.82%
  • Shares traded5.04k
  • 1 Year change51.03%
  • Beta0.3806
Data delayed at least 20 minutes, as of Feb 06 2026 19:14 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It has a cancer program, namely TREX1. It operates in more than 35 countries worldwide.

  • Revenue in USD (TTM)29.09bn
  • Net income in USD8.11bn
  • Incorporated1987
  • Employees17.60k
  • Location
    Gilead Sciences Inc333 LAKESIDE DRFOSTER CITY 94404-1147United StatesUSA
  • Phone+1 (302) 658-7581Fax+1 (302) 655-5049
  • Websitehttps://www.gilead.com/
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.